ReviewFEBS letters2018
Adenosine methylation as a molecular imprint defining the fate of RNA.
Review in FEBS letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Regulation of PSAT1 and PHGDH by m6A in endocrine-resistant breast cancer cells.Biochimica et biophysica acta. Molecular basis of disease · 2026Article
- Cherry plum powder alleviates excessive proliferation and inflammation of keratinocytes in psoriasis by reducing N6 methyladenosine-modified S100A4.Journal of molecular histology · 2026Article
- IGF2BP3 promotes progression of head and neck cancers through the circHECTD2/hsa_miR_4310/7157-5p/Smad2 signaling axis in an mMolecular cancer · 2026Article
- Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells.Functional & integrative genomics · 2025Article
- The dual mechanism of mCell death & disease · 2025Article
- Phase transition of WTAP regulates meLife · 2025Article
- Identifying human pre-mRNA cleavage and polyadenylation factors by genome-wide CRISPR screens using a dual fluorescence readthrough reporter.Nucleic acids research · 2024Article
- Emerging Roles and Mechanisms of RNA Modifications in Neurodegenerative Diseases and Glioma.Cells · 2024Review
- ExploringHorticulture research · 2024Article
- Review
- Changes in m6A in Steatotic Liver Disease.Genes · 2023Review
- Overview of mJournal of cancer research and clinical oncology · 2023Review
- METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.BMC gastroenterology · 2023Article
- Fragile X-Related Protein FXR1 Controls Human Adenovirus Capsid mRNA Metabolism.Journal of virology · 2023Article
- m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer.Journal of molecular endocrinology · 2023Review
- Polychlorinated biphenyls alter hepatic m6A mRNA methylation in a mouse model of environmental liver disease.Environmental research · 2023Article
- Knockdown of METTL16 disrupts learning and memory by reducing the stability of MAT2A mRNA.Cell death discovery · 2022Article
- NMDAR mediated dynamic changes in mScientific reports · 2022Article
- Regulation and roles of RNA modifications in aging-related diseases.Aging cell · 2022Review
- Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple lines of evidence suggest the RNA modification N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.